Tauklarify is an FDA-approved brain PET tracer that identifies tau tangle pathology in adults with cognitive impairment being evaluated for Alzheimer disease. For primary care patients, established use is selective referral testing with clinical evaluation and amyloid testing, while early-stage accuracy, staging, and prognosis remain uncertain.
Tauklarify, or florquinitau F 18 injection, is a radioactive tracer that makes tau neurofibrillary tangles visible on PET. Tangles are twisted tau protein deposits inside brain cells that track closely with Alzheimer symptoms. Primary care doctors do not order it for screening; they refer selected patients with memory or thinking changes for hospital-based imaging.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Who qualifies for the scan
- How well do readers agree
- How does it compare with older tau imaging
- What should primary care patients discuss
Who qualifies for the scan
The FDA approval covers adults with cognitive impairment who are being evaluated for Alzheimer disease to identify tau tangle pathology. Lantheus states in the FDA approval announcement that safety and effectiveness are not established for non-Alzheimer tauopathies. Performance may also be lower at earlier pathologic stages.
In practice, that means referral after history, exam, cognitive testing, and often amyloid evaluation. It does not mean testing for normal aging worries, family risk alone, or other movement and behavioral disorders. A memory-clinic team then decides if tau PET will change diagnosis or care.
How well do readers agree
Approval rested on two blinded-read studies pooling 617 participants from three trials. Five independent readers scored each scan as positive or negative against amyloid-PET plus cognition standards. NeurologyLive reports in its approval summary that positive agreement ranged from 68% to 88% and negative agreement from 93% to 99%.
Interreader reliability was strong, with Fleiss kappa values of 0.86 and 0.92. That supports consistent yes-or-no reads across centers. Positive reads are less consistent than negative reads, so borderline cases still need clinical judgment.
How does it compare with older tau imaging
A University of Pittsburgh head-to-head study in 682 people compared MK-6240, now called Tauklarify, with flortaucipir. MK-6240 detected tau more than twice as often in cognitively unimpaired people. It also better separated Alzheimer-related impairment, with an area under the curve of 0.93 versus 0.86.
Earlier signal matters because tau spreads before daily function fails. A more sensitive tracer can place a patient further along the Alzheimer pathway. It cannot by itself date onset, predict speed of decline, or select treatment without other findings.
What should primary care patients discuss
Use is selective and complementary, not routine screening. Ask about the reason for referral, how tau results combine with amyloid PET and clinical findings, and what follow-up each result would trigger.
Bring a full medication, smoking, breastfeeding, and radiation-exposure history to the imaging visit. Pharmacy Times notes in its clinical summary that a negative scan does not exclude tau pathology and a positive scan does not prove histopathologic tau. Safety data in 1,734 people showed mainly headache in 0.7% and nausea in 0.2%.
- confirm Alzheimer evaluation is the indication, not another tauopathy
- review amyloid status, cognition, and MRI or other workup
- avoid CYP1A2 inducers and smoking for 7 days before imaging when advised
- follow radiation precautions and pause breastfeeding for 4 hours after injection
You Might Also Like
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: What Is Established and What Remains Uncertain for Primary Care Patients
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: What Is Established and What Remains Uncertain for Primary Care Patients
- FDA’s 2026 PrecivityAD2 Alzheimer’s Blood Test Clearance: What Is Established and What Remains Uncertain for Primary Care Patients
